Published 7 days ago • loading... • Updated 7 days ago

Trial reports preliminary findings on cognitive function in early dementia patients

On Friday, June 19, 2026, lead investigator Kat Toups, MD, will present preliminary results from the Evanthea Dementia Reversal Trial at the Integrative and Personalised Medicine Congress in London.
Dementia affects more than 55 million people worldwide with limited therapeutic options to alter disease progression; the Evanthea trial proposes a new framework prioritizing individual biology and early identification of causes.
Participants in the 9-month randomized controlled trial were assigned to either a precision medicine treatment approach or a standard approach, with both groups undergoing baseline testing, MRI head scans, and monthly physician appointments.
Validating a 2022 proof-of-concept study, the data suggests cognitive decline is not irreversible; lead advisor Dale Bredesen, MD, said, "Meaningful cognitive recovery is very often possible."
Approximately 982,000 people live with dementia in the UK today, projected to rise to 1.4 million by 2040, underscoring the critical need for transformative treatment strategies the trial aims to provide.

Insights by Ground AI